Dr. John Ridden has almost 20 years of experience in both large and small BioPharma progressing a number of projects through preclinical research to candidate drug nomination. Following a DPhil in Clinical Biochemistry at Oxford John went on to complete a Postdoctoral position in Peter Parker’s lab at the Institute for Cancer Research working on identifying and characterising a new class of kinases involved in cancer. John then worked for a small biotech company working in oncology and dermatology therapy areas and from here moved to Pfizer for 7 years where he led a number of drug discovery projects in Cardiovascular and Tissue Repair research areas. Subsequently he moved to AstraZeneca where he worked for 11 years at a senior leadership level in target identification and translational research supporting Oncology, Respiratory and Inflammation, and Cardiovascular research areas.
Juergen DobmeyerActing Chief Medical Officer
Juergen Dobmeyer is a seasoned clinical lead and research physician. During the last 20 years Juergen has gained considerable experience in drug safety services, regulatory science, experimental and pharmaceutical medicine, leading and managing all phases of drug development from Proof of Concept Trials through to market support in several therapeutic areas with a focus on infectious diseases, immunology and oncology. Juergen supported multiple Phase 2 and 3 trials that led to the marketing authorization of new anti-microbial medications in different indications in both the US and Europe. Juergen has >20 years of experience as Consultant and Director of Clinical Operations at Galenus G.H. AG, a therapeutically focused Contract Research Organization headquartered in Switzerland. Previous to this, he had different management roles with increasing responsibility at Institute for Medical Statics, Frankfurt, Germany and IMS Health Germany covering drug safety services, medical affairs, portfolio optimization, forecasting and launch and brand management.
Dr. David CookChief Scientific Officer
David has a background in biochemistry, immunology and molecular biology with a PhD from Imperial College, London and three years of post-doctoral experience. David has worked in the pharmaceutical industry for AstraZeneca for more than 17 years in a wide variety of R&D roles both in the UK and the US. He initially worked in the respiratory and inflammation area and was responsible for identifying the mode-of-action for a new class of immunosuppressive. David moved into the safety functions six years ago since when he has led a number of global initiatives developing new approaches to improve the understanding of safety in new medicines. David has experience across the drug discovery and development pipeline from target selection to supporting market products and has worked on projects in many disease areas including Respiratory and Inflammation, Infection, Cardiovascular, CNS and Pain and Oncology.
Mark HollingworthFinance Director
Mark is an experienced finance leader with significant finance and business experience in bioscience, major pharmaceutical and other global R&D-led companies. After graduating from Edinburgh University Mark qualified as chartered management accountant in 1999 at BAe Systems and has gone on to spend most of his career in life sciences. He provided the financial leadership to a number of major change projects at AstraZeneca over 8 years, including as Finance Director to its transformational R&D Strategy project. Since leaving AstraZeneca in 2012, he has also built organisation capability in a variety of life sciences and healthcare companies as a consultant finance director, mainly in the anti-infectives therapy area.
Simon WallworkLegal Counsel
Simon is a corporate lawyer and partner at Slater Heelis LLP. With over 20 years experience advising on acquisitions, disposals, private equity and public market transactions, commercial agreements and joint ventures for a wide variety of clients including public and private companies, banks, venture capital funds and partnerships. Simon has worked within the Life Sciences sector for most of his career. He has a detailed knowledge of the market and has advised a number of companies from start-up, through funding to eventual sale.